期刊
CURRENT ONCOLOGY REPORTS
卷 11, 期 2, 页码 94-101出版社
SPRINGER
DOI: 10.1007/s11912-009-0015-5
关键词
-
类别
资金
- Bayer/Onyx
- NATIONAL CANCER INSTITUTE [R01CA121781] Funding Source: NIH RePORTER
The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据